Windhover Information, Intercontinental Mark Hopkins San Francisco
December 11-12, 2008
Biomarkers are hot – central to the new pharma business strategies. With attrition rates higher and trials ever more expensive, drug companies are insisting on development biomarkers. And Big Pharma’s sharpening focus on high-value specialty products means drugs targeted with biomarkers to particular patient groups are increasingly attractive.
But biomarker strategies are far from straightforward. Getting biomarkers approved for particular drugs can add time and cost; biomarker work paid for by pioneer drugs can be exploited by follow-ons – to the pioneer’s competitive disadvantage. And dealmakers are only beginning to figure out the governance and financing rules of biomarker development. With in-depth case studies and interactive panels of experts, Windhover’s groundbreaking Pharma Business Strategies for Biomarkers will probe the strategies, dealmaking and economics of building biopharma businesses in the era of biomarkers.
Why should you participate in Windhover’s Pharma Business Strategies for Biomarkers?
Discover key opportunities in biomarker discovery, development and commercialization
Get expert advice you can apply to your business from top minds in the industry, as only Windhover can deliver
Hear real-life case studies on the rationale behind a company’s biomarker strategy
Understand new development strategies and their implications for dealmaking
Find out how biomarkers are being used to reduce attrition in development
Learn which companies demand biomarkers as requirements for dealmaking – and why
Find out whether a combined therapeutics/diagnostics business makes sense
Decide whether you should sell your own biomarker with your therapeutic, give it away …or partner with a diagnostics company
Discover what’s likely to happen with biomarker approvals
Understand how biomarkers can destroy value in an associated drug
Don’t miss this unprecedented opportunity to join other senior-level executives in discussing the business case for and against biomarker technologies, and helping determine the future application of biomarkers in this competitive environment of commercializing new products.
Seating is limited. Register online today and save.